Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity
2020-002953-11Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide 50 mg with Placebo (2 arms). Primary endpoints: Relative change in body weight and Change in physical function. Started May 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2020-002953-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002953-11.